Log in

NASDAQ:SURFSurface Oncology Stock Price, Forecast & News

+0.08 (+1.73 %)
(As of 06/5/2020 04:00 PM ET)
Today's Range
Now: $4.70
50-Day Range
MA: $3.46
52-Week Range
Now: $4.70
Volume505,617 shs
Average Volume5.90 million shs
Market Capitalization$133.10 million
P/E RatioN/A
Dividend YieldN/A
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company develops human immunoglobulin isotype G4 monoclonal antibodies, including SRF231 inhibiting CD47; NZV930 inhibiting CD73; SRF617 inhibiting CD39; and SRF388 targeting interleukin 27. It also develops various earlier stage programs that targets other critical components of the tumor microenvironment, including regulatory T cells and natural killer cells. The company has a strategic collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies. Surface Oncology, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Read More
Surface Oncology logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.72 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:SURF



Sales & Book Value

Annual Sales$15.36 million
Book Value$2.03 per share


Net Income$-54,790,000.00


Market Cap$133.10 million
Next Earnings Date8/5/2020 (Estimated)
OptionableNot Optionable

Receive SURF News and Ratings via Email

Sign-up to receive the latest news and ratings for SURF and its competitors with MarketBeat's FREE daily newsletter.

Surface Oncology (NASDAQ:SURF) Frequently Asked Questions

How has Surface Oncology's stock been impacted by COVID-19 (Coronavirus)?

Surface Oncology's stock was trading at $2.37 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SURF stock has increased by 98.3% and is now trading at $4.70. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Surface Oncology?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Surface Oncology in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Surface Oncology.

When is Surface Oncology's next earnings date?

Surface Oncology is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Surface Oncology.

How were Surface Oncology's earnings last quarter?

Surface Oncology Inc (NASDAQ:SURF) issued its quarterly earnings results on Tuesday, May, 12th. The company reported $0.74 earnings per share for the quarter, topping analysts' consensus estimates of $0.43 by $0.31. The business earned $38.59 million during the quarter, compared to the consensus estimate of $38.59 million. Surface Oncology had a negative net margin of 70.90% and a negative return on equity of 38.44%. View Surface Oncology's earnings history.

Has Surface Oncology been receiving favorable news coverage?

Press coverage about SURF stock has trended positive this week, InfoTrie reports. The research group ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Surface Oncology earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the next few days. View the latest news aboutSurface Oncology.

Are investors shorting Surface Oncology?

Surface Oncology saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 97,700 shares, a drop of 27.0% from the April 30th total of 133,800 shares. Based on an average daily volume of 121,000 shares, the short-interest ratio is currently 0.8 days. Currently, 0.7% of the company's shares are sold short. View Surface Oncology's Current Options Chain.

Who are some of Surface Oncology's key competitors?

What other stocks do shareholders of Surface Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Surface Oncology investors own include Allena Pharmaceuticals (ALNA), Verizon Communications (VZ), Enterprise Products Partners (EPD), Alteryx (AYX), Netflix (NFLX), Vertex Pharmaceuticals (VRTX), Xilinx (XLNX), Carnival (CCL), Enphase Energy (ENPH) and Pfizer (PFE).

Who are Surface Oncology's key executives?

Surface Oncology's management team includes the following people:
  • Mr. Daniel S. Lynch, Exec. Chairman (Age 61)
  • Mr. J. Jeffrey Goater, CEO, Pres & Director (Age 44)
  • Dr. Vito J. Palombella, Chief Scientific Officer (Age 56)
  • Dr. Robert W. Ross, Chief Medical Officer (Age 45)
  • Ms. Jessica Fees, Sr. VP of Fin. & Bus. Operations and Treasurer (Age 47)

When did Surface Oncology IPO?

(SURF) raised $84 million in an initial public offering (IPO) on Thursday, April 19th 2018. The company issued 6,000,000 shares at $13.00-$15.00 per share. Goldman Sachs, Cowen and Evercore ISI acted as the underwriters for the IPO.

What is Surface Oncology's stock symbol?

Surface Oncology trades on the NASDAQ under the ticker symbol "SURF."

Who are Surface Oncology's major shareholders?

Surface Oncology's stock is owned by many different retail and institutional investors. Top institutional shareholders include Victory Capital Management Inc. (2.40%), Victory Capital Management Inc. (2.40%), BlackRock Inc. (0.75%), Acadian Asset Management LLC (0.48%) and Squarepoint Ops LLC (0.05%). View institutional ownership trends for Surface Oncology.

Which major investors are selling Surface Oncology stock?

SURF stock was sold by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC, and BlackRock Inc.. View insider buying and selling activity for Surface Oncology.

Which major investors are buying Surface Oncology stock?

SURF stock was acquired by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Victory Capital Management Inc., and Acadian Asset Management LLC. View insider buying and selling activity for Surface Oncology.

How do I buy shares of Surface Oncology?

Shares of SURF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Surface Oncology's stock price today?

One share of SURF stock can currently be purchased for approximately $4.70.

How big of a company is Surface Oncology?

Surface Oncology has a market capitalization of $133.10 million and generates $15.36 million in revenue each year. The company earns $-54,790,000.00 in net income (profit) each year or ($1.97) on an earnings per share basis. Surface Oncology employs 76 workers across the globe.

What is Surface Oncology's official website?

The official website for Surface Oncology is www.surfaceoncology.com.

How can I contact Surface Oncology?

Surface Oncology's mailing address is 50 HAMPSHIRE STREET 8TH FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-714-4096 or via email at [email protected]

This page was last updated on 6/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.